Search
International Breast Cancer Conference Features UCSF Health Experts
Breast cancer experts from UCSF Health will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most prestigious breast cancer conference. This year’s meeting will be held Dec. 7-10.Breast Cancer Risk Calculator Can Assess Risk of Advanced Breast Cancer
Upcoming Conference to Focus on Breast Density and Prediction of Advanced and Interval Breast Cancer RiskScreening Guidelines for Common Cancers: A Lifesaving Update
In just 35 minutes, hematologist-oncologist Akshiv Malhotra, MD, presents the current recommendations on cervical, breast, colon and lung cancers, breaking down the test options for each and when to start tests based on a patient’s risk.Immune Cells Leave Fingerprints on Tumors Metastasized to the Brain Offering Clues to Future Therapies
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types. Their findings, published the February 17 issue of CELL, provide a potential roadmap for metastatic tumor formation that could be used to design therapies to improve the treatment of metastasized patients.Cancer Preventive Care: Empower Your Patients to Take Small-But-Significant Steps
Patients worry about cancer but struggle to make lifestyle changes. Here’s how to discuss factors they can control and realistic steps they can take.International Hematologic Conference Features UCSF Health Experts
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 63rd Annual Meeting and Exposition. This year’s meeting will be held in Atlanta, Georgia – and virtually – from December 11-14, 2021.UCSF’s Lawrence Fong, MD, Earns NCI Award for Cancer Immunotherapy Research
The National Cancer Institute (NCI)has honored Lawrence H. Fong, MD, leader of the UC San Francisco Cancer Immunotherapy Program, with an Outstanding Investigator Award (R35).These awards support investigators who have significant records of productivity in cancer research with multiyear funding for projects of exceptional potential.Inclusion of New Risk Factors Can Improve Prediction of Invasive Breast Cancer
UCSF researchers update Breast Cancer Surveillance Consortium model to account for BMI and other familial risk factors.Katherine Van Loon Named Editor-in-Chief of JCO Global Oncology
Katherine Van Loon, MD, MPH, has been appointed as the next editor-in-chief of JCO Global Oncology (JCO GO), an American Society of Clinical Oncology (ASCO) journal.UCSF Surgeons Perform First Pure Robotic Whipple Surgery in the Bay Area
Gastrointestinal surgeons at UC San Francisco have performed the first pure robotically assisted Whipple surgery in San Francisco.UCSF Osher Center Overview: Integrative Medicine’s Value for Providers and Patients
Sanford C. Newmark, MD, medical director of the UCSF Osher Center for Integrative Medicine, explains what integrative medicine is (hint: it’s neither “alternative medicine” nor homeopathy) and how referred patients can benefit from its proven techniques.Cardio-Oncology & Immunology: Specialized Cardiovascular Care for Cancer Patients
Led by a multidisciplinary team of specialists and researchers, our program optimizes the cardiovascular health of cancer patients and cancer survivors.High Risk for Breast Cancer: Methods and Schedules to Ensure Optimal Screening
Hematologist-oncologist Elham Vosoughi, MD, starts with an update on breast cancer stats, noting that incidence in the United States is increasing by 1% every year – with an even sharper rise for women under 50.Sorting Cancers by “Immune Archetypes” Represents Potential New Approach to Developing Precision Immunotherapies
Using data from over 300 patient tumors, UCSF researchers have described 12 classes of “immune archetypes” to classify cancer tumors. Their findings, published today in CELL, reveal that cancers from different parts of the body are immunologically similar to one another. These classifications provide unique strategies for enhancing each patient’s choice of cancer immunotherapies.UCSF500 Cancer Gene Panel Test
The UCSF500 Cancer Gene Panel leverages world-class expertise for advanced cancer cases. Designed by our leading cancer specialists, the UCSF500 offers unparalleled depth and precision in genetic analysis.Lung Cancer Screening: Who, How and When to Refer
†horacic radiologist Brett M. Elicker, MD, and thoracic surgeon Johannes Kratz, MD, present about current lung cancer screening guidelines: who, how, and when to refer.UCSF Clinic Fills Unmet Need for Managing Oral Side Effects of Cancer Therapies
As advances in cancer treatments have expanded, so has the number of side effects that impact the mouth. Oral medicine specialists at UC San Francisco are working to mitigate these often-debilitating problems, which affect the majority of patients undergoing or recovering from cancer therapy.Genomic Sequencing Is Changing Diagnosis, Treatment for Patients with Brain Cancer
Patients diagnosed with a type of brain tumor survived for longer when they were treated aggressively with surgery, radiation and chemotherapy.Can Lymph Nodes Boost the Success of Cancer Immunotherapy?
New data from a clinical trial show therapies may activate lymph nodes to produce tumor-tackling T cells.UCSF Cancer Researcher Thomas Martin Receives $4.6 million CIRM Grant
UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T cell therapy for multiple myeloma, the second most common malignancy among blood cancers.Brachytherapy Improves Outcomes for Cervical Cancer Patients
Patients with locally advanced cervical cancer who receive chemoradiation therapy and brachytherapy and complete treatment within eight weeks have a superior overall survival rate compared to those who don’t receive this treatment, according to a UCSF study.First-line Pembrolizumab Plus Chemotherapy May Benefit Patients with Advanced Biliary Tract Cancers
The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial.Response to Cancer Immunotherapy May Be Affected by Genes We Carry from Birth
A new study finds that inherited genetic variation plays a role in who is likely to benefit from checkpoint inhibitors, which release the immune system’s brakes so it can attack cancer.Prostate Cancer Study: More Health Benefits from Plant-Based Diet
Men with prostate cancer could significantly reduce the chances of the disease worsening by eating more fruits, vegetables, nuts and olive oil, according to new research by UC San Francisco.